An update on infantile haemangiomas

British Journal of Dermatology

Volumn 169, Issue 1, 2013, Pages 11-

  Hoeger, P H ^a  

^a Wilhelmstift Children's Hospital   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; GLUCOSE TRANSPORTER 1; ANTINEOPLASTIC AGENT; PROPRANOLOL;

ANGIOGENESIS; DEFORMITY; EDITORIAL; HEMANGIOMA; HYPOXIA; LOW LEVEL LASER THERAPY; PRIORITY JOURNAL; ULCER; HUMAN; INFANT; SKIN NEOPLASMS;

ANTINEOPLASTIC AGENTS; HEMANGIOMA; HUMANS; INFANT; PROPRANOLOL; SKIN NEOPLASMS;

EID: 84879956545     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.12448     Document Type: Editorial

References (9)

1. Kleinman ME, Greives MR, Churgin SS, et al,. Hypoxia-induced mediators of stem/progenitor cell trafficking are increased in children with hemangioma. Arterioscler Thromb Vasc Biol 2007; 27: 2664-70.
2. Boye E, Olsen BR,. Signaling mechanisms in infantile hemangioma. Curr Opin Hematol 2009; 16: 202-8.
3. Boscolo E, Stewart CL, Greenberger S, et al,. JAGGED1 signaling regulates hemangioma stem cell-to-pericyte/vascular smooth muscle cell differentiation. Arterioscler Thromb Vasc Biol 2011; 31: 2181-92.
4. North PE, Waner M, Mizeracki A, Mihm MC,. GLUT1: a newly discovered immunohistochemical marker for juvenile hemangiomas. Hum Pathol 2000; 31: 11-22.
5. Metry D, Heyer G, Hess C, et al,. Consensus statement on diagnostic criteria for PHACE syndrome. Pediatrics 2009; 124: 1447-56.
6. Léauté-Labrèze C, Dumas de la Roque E, Hubiche T, et al,. Propranolol for severe hemangiomas of infancy. N Engl J Med 2008; 358: 2649-51.
7. Marqueling AL, Oza V, Frieden IJ, Puttgen KB,. Propranolol and infantile hemangiomas four years later: a systematic review. Pediatr Dermatol 2013; 30: 182-91.
8. Greenberger S, Bischoff J,. Pathogenesis of infantile haemangioma. Br J Dermatol 2013; 169: 12-19.
9. Luu M, Frieden IJ,. Haemangioma: clinical course, complications and management. Br J Dermatol 2013; 169: 20-30.